Search clinical trials for: PF-00299804

Total 1303 results

Pfizer

Terminated

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

Neoplasms

United States
Pfizer

Completed

A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function

Renal Insufficiency, Chronic

United States
Pfizer

Completed

Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery

Reduction of Hypertrophic Skin Scarring

United States, Germany, Hungary, Spain
Pfizer

Terminated

A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study

Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery

United States
Pfizer

Terminated

This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia
Pfizer

Completed

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

Healthy

United States
Pfizer

Completed

A Study Of Three PF-05190457 Formulations In Healthy Volunteers

Diabetes Mellitus, Type 2

Singapore
Pfizer

Completed

A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption

Diabetes Mellitus, Type 2

Belgium
Pfizer

Completed

Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Influenza, Human

United States
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Pfizer

Completed

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

Healthy

United States
Pfizer

Completed

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

Healthy

Belgium
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Pfizer

Terminated

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

Healthy

United States
Pfizer

Terminated

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Gastric Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Junction Cancer | Urothelial Cancer | Head and Neck Squamous Cell Carcinomas

United States, Japan
Fred Hutchinson Cancer Center
Pfizer

Terminated

Glasdegib for Chronic Graft-Versus-Host Disease

Chronic Graft Versus Host Disease | Fasciitis

United States
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Pfizer

Completed

A Study Of PF-04449913 In Select Hematologic Malignancies

Hematologic Malignancies

United States, Italy
Pfizer

Completed

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

Colorectal Cancer | Pancreatic Cancer | Cachexia | Non-Small-Cell Lung Cancer

United States
NCIC Clinical Trials Group
Pfizer

Completed

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

Canada
Pfizer

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States
Pfizer

Completed

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

Healthy Participants

United States
Pfizer

Completed

PF-06741086 Long-term Treatment in Severe Hemophilia

Hemophilia A or B

Poland, Switzerland, South Africa, United States, Croatia, Brazil, Chile
Pfizer

Terminated

An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Japan, Italy
Pfizer

Terminated

PF-06671008 Dose Escalation Study in Advanced Solid Tumors

Neoplasms

United States
Pfizer

Terminated

First in Patient Study for PF-06840003 in Malignant Gliomas

Astrocytoma | Malignant Glioma | Oligodendroglioma

United States
Pfizer

Terminated

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

Triple Negative Breast Neoplasms

Spain, United Kingdom, United States, Italy, Hungary, Poland
Pfizer

Completed

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus (BUTTERFLY)

Lupus Erythematosus, Systemic

United States, Germany, Taiwan, Hungary, Poland, Colombia, Argentina, Romania, Chile, Puerto Rico, Korea, Republic of, Moldova, Republic of, Peru
Pfizer

Completed

Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects

Healthy

United States
Pfizer

Withdrawn

A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers

Healthy
Pfizer

Completed

A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation

Healthy

United States
Pfizer

Completed

A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee

Pain

Belgium
Pfizer

Completed

A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State

Pain

Belgium
Pfizer

Completed

Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors

Solid Tumors

United States, Belgium
Pfizer

Completed

A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

Healthy

United States
Pfizer

Completed

A Study Comparing PF-05089771 TS Tablet to PF-05089771 TS Oral Dispersion In The Fasted State And To PF-05089771 TS Tablet In The Fasted And Fed State

Pain

Belgium
Pfizer

Completed

A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects

Healthy

Singapore
Pfizer

Completed

Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429

Healthy

Belgium
Pfizer

Completed

The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.

Pain

Belgium
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single Dose Of PF-04995274 In Healthy Adult Volunteers

Healthy

Belgium
Pfizer
Bristol-Myers Squibb

Completed

A Single Dose Study Of PF-04620110 In Healthy Subjects

Healthy

Singapore
Pfizer

Completed

A Study To Observe The Performance Of A Tablet Form Of PF-04531083 As Evidenced By The Concentration Of PF-04531083 In The Blood With Time Following Oral Administration To Healthy Volunteers.

Chronic Pain

Belgium
Pfizer

Completed

A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body

Human Immunodeficiency Virus (HIV)

United Kingdom
Pfizer

Completed

A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03526299 In Healthy Adult Volunteers

Healthy

Singapore
Pfizer

Completed

A Study To Evaluate Whether Food Affects The Plasma Drug Levels Of A 35 mg Single Dose Of PF-04447943 Taken Orally In Healthy Adult Participants

Healthy

United States
Pfizer

Completed

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

Healthy | Elderly

United States
Pfizer

Completed

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers

Healthy Volunteers

Belgium
Shire

Completed

Long-Term Safety Of PF-00547659 In Ulcerative Colitis (TURANDOT II)

Ulcerative Colitis

Korea, Republic of, United States, Spain, Australia, Canada, Israel, Serbia, Netherlands, Belgium, Italy, New Zealand, Austria, Bulgaria, Czechia, France, Germany, Hungary, Poland, Russian Federation, Slovakia, South Africa

3

Subscribe